Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 11.6% – Should You Buy?

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) were up 11.6% during trading on Thursday . The company traded as high as $25.10 and last traded at $24.8950. Approximately 44,391 shares changed hands during trading, a decline of 37% from the average daily volume of 70,323 shares. The stock had previously closed at $22.31.

Wall Street Analysts Forecast Growth

LYEL has been the topic of a number of research reports. Wall Street Zen upgraded Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Monday, September 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Wednesday, October 8th. Finally, HC Wainwright restated a “neutral” rating and set a $20.00 price target (up from $10.00) on shares of Lyell Immunopharma in a research report on Monday, November 24th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Lyell Immunopharma has a consensus rating of “Reduce” and an average price target of $20.00.

Lyell Immunopharma Price Performance

The business’s 50 day moving average is $17.93 and its 200-day moving average is $13.13. The company has a market cap of $533.66 million, a PE ratio of -1.11 and a beta of -0.11.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.81) by $0.68. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.01 million. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%. As a group, sell-side analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Institutional Trading of Lyell Immunopharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. ARCH Venture Management LLC acquired a new stake in Lyell Immunopharma during the 2nd quarter worth $16,113,000. Almitas Capital LLC boosted its stake in shares of Lyell Immunopharma by 136.3% during the first quarter. Almitas Capital LLC now owns 2,482,606 shares of the company’s stock worth $1,336,000 after buying an additional 1,432,086 shares during the period. Nuveen LLC purchased a new position in shares of Lyell Immunopharma during the first quarter worth about $345,000. Acadian Asset Management LLC increased its position in Lyell Immunopharma by 204.2% in the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after acquiring an additional 443,614 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Lyell Immunopharma by 76.0% in the 3rd quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock valued at $12,651,000 after purchasing an additional 336,378 shares during the last quarter. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.